MARKET

ONTX

ONTX

Onconova
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3121
-0.0078
-2.44%
Pre Market: 0.3150 +0.0029 +0.93% 07:01 03/31 EDT
OPEN
0.3100
PREV CLOSE
0.3199
HIGH
0.3149
LOW
0.2934
VOLUME
6.05M
TURNOVER
--
52 WEEK HIGH
4.450
52 WEEK LOW
0.1027
MARKET CAP
4.49M
P/E (TTM)
-0.1028
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ONTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ONTX stock price target is 1.767 with a high estimate of 2.000 and a low estimate of 1.300.

EPS

ONTX News

More
  • Allakos Data, And Other News: The Good, Bad, And Ugly Of Biopharma
  • Seeking Alpha - Article · 4d ago
  • Onconova Therapeutics (ONTX) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 5d ago
  • Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 6d ago
  • Onconova Therapeutics EPS misses by $0.68, misses on revenue
  • seekingalpha · 6d ago

Industry

Pharmaceuticals
+4.97%
Pharmaceuticals & Medical Research
+4.75%

Hot Stocks

Symbol
Price
%Change

About ONTX

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
More

Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTX stock news, and many more online research tools to help you make informed decisions.